Physicians' Academy for Cardiovascular Education

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon - Boston, MA, USA

Video navigation menu

  • Effects of sacubitril/valsartan in the PARAMOUNT trial 01:13
  • Design of the PARAGON-HF trial 02:35
  • Results of the PARAGON-HF trial 05:58
  • An analysis of combined data of the PARADIGM-HF and PARAGON-HF trials 10:27
  • Renal outcomes in PARAGON-HF 12:57

An analysis using data from both PARADIGM-HF and PARAGON-HF shows that with sacubitril/valsartan

  • A. benefit extends to ejection fraction of ~60%
  • B. benefit is seen only in HFrEF patients with ejection fraction up to 40%
  • C. benefit is seen over the total range of ejection fraction
  • D. benefit in men extends to a higher ejection fraction than in women
Show correct answer

Educational information

This educational video is the first part of a serie called "Reviewing HFpEF: Lessons and implications from PARAGON-HF" that is aimed to give cardiologists and other health care professionals involved in the management of heart failure a well-balanced expert view on findings derived from the PARAGON-HF trial.


Scott David Solomon is Director Noninvasive Cardiology, Cardiovascular Medicine, Brigham and Women's Hospital and Professor at Harvard Medical School, Boston, MA, USA.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Novartis.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: